肥胖症手术后体重减轻不足患者应用利拉鲁肽辅助药物治疗的作用。
The role of adjuvant pharmacotherapy with liraglutide for patients with inadequate weight loss following bariatric surgery.
机构信息
Upper GI Surgery Unit, St George Hospital, Sydney, Australia.
Faculty of Medicine, University of Sydney, Sydney, Australia.
出版信息
Langenbecks Arch Surg. 2023 Mar 3;408(1):115. doi: 10.1007/s00423-023-02805-8.
PURPOSE
Despite the benefits of bariatric surgery for many patients, there are a proportion of patients who do not achieve adequate weight loss. We evaluate the role of liraglutide as adjuvant pharmacotherapy in those who respond poorly to weight loss surgery.
MATERIALS AND METHODS
A non-controlled, prospective, open-label cohort study in which participants are prescribed liraglutide following inadequate response to weight loss surgery. The efficacy and tolerability of liraglutide was measured through measurement of BMI and monitoring of side effect profile.
RESULTS
A total of 68 partial responders to bariatric surgery were included in the study, 2 participants were lost to follow-up. Overall 89.7% lost weight on liraglutide, with 22.1% showing a good response (>10% total body weight loss). There were 41 patients who discontinued liraglutide mainly due to cost.
CONCLUSION
Liraglutide is efficacious in achieving weight loss and reasonably well tolerated in patients who have inadequate weight loss post-bariatric surgery.
目的
尽管减重手术对许多患者有益，但仍有一部分患者无法实现足够的体重减轻。我们评估了利拉鲁肽作为辅助药物治疗在那些对减重手术反应不佳的患者中的作用。
材料和方法
这是一项非对照、前瞻性、开放标签的队列研究，参与者在减重手术后反应不足时被开处利拉鲁肽。通过测量 BMI 和监测副作用谱来评估利拉鲁肽的疗效和耐受性。
结果
共有 68 名对减重手术反应不足的患者纳入研究，其中 2 名患者失访。总体而言，89.7%的患者在服用利拉鲁肽后体重减轻，其中 22.1%的患者反应良好（>10%的总体体重减轻）。有 41 名患者因费用原因停止使用利拉鲁肽。
结论
利拉鲁肽在减重手术后体重减轻方面是有效的，并且在患者中具有良好的耐受性。
Zotero 插件